Related Experiment Videos
Cyclosporine-induced hyperuricemia and gout
H Y Lin1, L L Rocher, M A McQuillan
1Human Purine Research Center, University Hospital, Ann Arbor, Mich.
The New England Journal of Medicine
|August 3, 1989
Summary
Cyclosporine therapy frequently causes hyperuricemia and gout in renal transplant patients due to reduced kidney urate clearance. This leads to significant morbidity, particularly when combined with diuretics.
Area of Science:
- Nephrology
- Immunosuppression Therapy
- Metabolic Disorders
Background:
- Cyclosporine is a key immunosuppressant in renal transplantation.
- Hyperuricemia and gout are potential complications of immunosuppressive drugs.
- Understanding the link between cyclosporine and uric acid metabolism is crucial for patient management.
Purpose of the Study:
- To determine the incidence of hyperuricemia and gout in renal transplant recipients on cyclosporine.
- To investigate the underlying mechanisms of hyperuricemia during cyclosporine treatment.
- To compare these complications with those in patients receiving azathioprine.
Main Methods:
- Prospective study comparing cyclosporine/prednisone (n=129) with azathioprine/prednisone (n=168) in renal transplant recipients.
- Monitoring of serum creatinine, serum urate levels, and incidence of gout.
- Analysis of urate metabolism and renal clearance in a subgroup of patients.
Main Results:
- Hyperuricemia was significantly more common in the cyclosporine group (84%) compared to the azathioprine group (30%).
- Gout developed in 7% of cyclosporine recipients, with no cases in the azathioprine group.
- Diuretic use increased the risk of elevated serum urate levels in both treatment groups.
Conclusions:
- Hyperuricemia is a frequent complication of cyclosporine therapy in renal transplant patients.
- The primary cause is a reduction in renal urate clearance, not altered urate turnover.
- Gouty arthritis contributes significantly to patient morbidity under cyclosporine treatment.